ARCT Q3 2025 Earnings — Arcturus Therapeutics Holdings Inc. Revenue & Financial Results | Market Cap Arena

ARCTArcturus Therapeutics Holdings Inc.

$217M

Q3 2025 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$17M-55.8% YoY

Gross Profit

$14M80.5% margin

Operating Income

-$17M-96.3% margin

Net Income

-$13M-78.4% margin

EPS (Diluted)

$-0.49

QoQ Revenue Growth

-30.0%

Cash Flow

Operating Cash Flow

-$17M

Free Cash Flow

-$17M

Stock-Based Comp.

$6M

Balance Sheet

Total Assets

$282M

Total Liabilities

$58M

Stockholders' Equity

$225M

Cash & Equivalents

$180M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$17M	$39M	-55.8%
Gross Profit	$14M	$39M	-64.4%
Operating Income	-$17M	-$11M	-53.8%
Net Income	-$13M	-$7M	-94.8%

Revenue Segments

Collaboration Revenue

$14M83%

Grant

$3M17%